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Abstract: Insulin resistance, diabetes mellitus, and metabolic syndrome in patients with 
human immunodeficiency virus (HIV) infection are increasingly being reported in the global 
medical literature. This cross-sectional study was done to describe the occurrence of metabolic 
syndrome, diabetes mellitus, and insulin resistance in HIV-positive patients in a tertiary   referral 
center in South India. A total of 60 patients who had HIV infection for 12 months or more 
were enrolled in the study. Of these, 30 patients were antiretroviral therapy (ART)-naïve, and 
30 were treated with ART. Biochemical estimations (fasting blood glucose, 75 g oral glucose 
tolerance test, lipid profile, and fasting insulin) and anthropometric measurements (height, 
weight, and waist circumference) were performed for each patient. Metabolic syndrome was 
diagnosed using National Cholesterol Education Program–Adult Treatment Plan III criteria, 
and insulin resistance was calculated applying the homeostasis model assessment method. 
Diabetes mellitus, impaired fasting glycemia, and impaired glucose tolerance were diagnosed 
based on American Diabetes Association criteria. A high prevalence of metabolic syndrome 
was observed in patients with HIV (16/60), and was more prevalent in the ART-treated group 
(13/30; P = 0.028). Similarly, insulin resistance was also noted to be high (24/60), and of 
these patients, 15 were on ART. Seventy-five percent of patients with metabolic syndrome 
had i  nsulin resistance. Diabetes was diagnosed in one patient who was ART-naïve and in six 
patients who were on ART. Our observations suggest an increased prevalence of metabolic 
syndrome, insulin resistance, and diabetes mellitus in ART-treated patients. These warrant 
attention and substantiation with larger studies. While ART improves survival, it may lead on 
to cardiovascular morbidity and mortality, especially in the Indian subcontinent where there 
is a genetic predisposition to cardiovascular risk.
Keywords: human immunodeficiency virus (HIV) infection, metabolic syndrome, insulin 
resistance, diabetes mellitus
Introduction
Human immunodeficiency virus (HIV), which was first discovered in 1981, has now 
infected more than two million people in India. The introduction of antiretroviral 
therapy (ART) has resulted in significant reductions in mortality and morbidity of these 
patients. However, the occurrence of insulin resistance and metabolic syndrome has 
been reported as a side effect of this therapy.1 The drugs implicated include nucleoside 
reverse transcriptase inhibitors (major components of first-line therapy in India) and 
also protease inhibitors (components of current second-line therapy in India). With 
alteration in insulin sensitivity, dysglycemia, dyslipidemia, hypertension, and body 
fat abnormalities, there are concerns about the long-term risks of ART.2 In India, International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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where there is genetic predisposition to insulin resistance and 
cardiovascular risk,3,4 this impact may be significant. Hence, 
this study was undertaken to assess the prevalence of these 
conditions in HIV-infected patients.
The aims of the study were to: 1) estimate the prevalence 
of metabolic syndrome, insulin resistance, and diabetes 
  mellitus in HIV-infected patients on ART; and 2) compare 
the prevalence of these conditions between patients who are 
on ART and those who are ART-naïve.
Methods
This is a cross-sectional study involving HIV-positive 
patients conducted in a tertiary referral centre in Bangalore. 
Patients were enrolled into the study if they were aged over 
18 years, had HIV infection for more than 12 months, and 
were on ART (ART-treated group) or had HIV infection 
for more than 12 months but were not on ART (ART-naïve 
group). Patients were not included in the study if diabetes 
mellitus,   hypertension, dyslipidemia, coronary artery disease, 
malignancy, sleep apnea, or chronic renal failure were present 
prior to starting ART or if they were nonadherent to ART.
Patients who satisfied the criteria were informed of 
the study and its details, following which a consent form 
was signed. The demographic details were collected from 
each patient and entered into the pro-forma. Subsequent to 
this, a detailed history was taken, and a thorough physical 
e  xamination was done. The anthropometric measurements 
were done by a skilled nutritionist, and these were height, 
weight, and waist circumference, measured using height 
scale, weighing machine, and inch tape, respectively, 
s  tandardized regularly in the St. John’s Medical College 
Nutrition Research Centre. Height was recorded to the 
nearest centimeter, and weight was recorded to the nearest 
0.5 kg. Waist girth was measured at the point between the 
iliac crest and the lower margin of the ribs and rounded to 
the nearest centimeter.
After an overnight fast, blood samples were drawn from 
each patient. Following this, 75 g glucose was administered, 
and at 2 hours another blood sample was drawn. Blood 
glucose levels, both fasting and post glucose load, were 
estimated using the hexokinase (enzymatic) method spec-
trophotometrically in R×L dimension automated equipment. 
The total cholesterol was determined using the cholesterol 
oxidase and cholesterol esterase method. High-density lipo-
protein (HDL) cholesterol was estimated by the automated 
enzymatic method. Triglycerides were determined using the 
lipoprotein lipase/glucokinase enzymatic procedure. The 
lipid profile was estimated using Dade Behring equipment. 
Fasting insulin levels were done using chemiluminescence 
method on immulite equipment from Diagnostics Product 
Corporation (Kolkata, India). All biochemical procedures 
were done in accordance with the International Federation 
of Clinical Chemistry (IFCC) quality control. The lab is 
under internal and external quality control and is National 
Accreditation Board for Testing and Calibration Laboratories 
(NABL)-accredited. CD-4 counts were done in the depart-
ment of microbiology or private labs.
Metabolic syndrome was defined using National 
Cholesterol Education Program–Adult Treatment Plan III 
(NCEP–ATP III) 2001 criteria.5 If three or more of the 
following criteria were present, metabolic syndrome was 
diagnosed:
•	 Waist circumference more than 102 cm in men and 88 cm 
in women,
•	 Triglycerides more than 150 mg/dL,
•	 HDL cholesterol less than 40 mg/dL in men and less than 
50 mg/dL in women,
•	 Blood pressure more than or equal to 130/85 mm Hg,
•	 Fasting glucose more than 110 mg/dL.
Insulin resistance (IR) was calculated using the homeo-
static model assessment of insulin resistance (HOMA-IR). 
This was obtained using the formula:6
 
  
    
A cutoff value of 1.93 was taken as IR, based on the 
Chennai Urban Population Study.7
Diabetes mellitus, impaired fasting 
glucose, and impaired glucose tolerance
The following criteria were used to classify hyperglycemia:8
•	 Fasting plasma glucose (FPG) , 100 mg/dL (5.6 mmol/L) = 
normal fasting glucose,
•	 FPG 100–125 mg/dL (5.6–6.9 mmol/L) = impaired 
  fasting glucose (IFG),
•	 FPG $ 126 mg/dL (7.0 mmol/L) = provisional diagnosis 
of diabetes.
The corresponding categories when the oral glucose 
tolerance test (OGTT) is used are the following:
•	 Two-hour postload glucose ,140 mg/dL (7.8 mmol/L) = 
normal glucose tolerance,
•	 Two-hour  postload  glucose  140–199  mg/dL 
(7.8–11.1 mmol/L) = IGT (impaired glucose tolerance),
•	 Two-hour postload glucose $200 mg/dL (11.1 mmol/L) = 
provisional diagnosis of diabetes.
Fasting insulin level (micro IU)   fasting glucose (mmol/l × ) )
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ethics
Approval from the Institutional Ethics Review Board was 
obtained prior to commencement of the study. All patients 
were provided with details of the aims of the study and the 
procedure following enrollment. A consent form was signed 
by all patients who were included in the study.
statistics
The data were analyzed using SPSS software (version 16; 
SPSS Inc., Chicago, IL). Student’s t-test was done to compare 
numerical variables in the two groups. Chi square test or 
Fisher’s exact test were used for ordinal variables.
Results
A total of 60 patients were enrolled in the study. Of these, 
30 patients were ART-naïve, and 30 were treated with 
ART. The mean duration of ART was 41.5 months (range 
12–108 months). There were 23 males and seven females 
in the ART-treated group and 21 males and nine females in 
the ART-naïve group. The mean age of patients in the ART-
treated group was 41.63 (±10.94), while that in the ART 
group was 40.6 (±9.48). The mean duration of   disease (HIV) 
was 53.3 (±27.76) months in the ART-treated group and 
17.20 (±9.18) months in the ART-naïve group. Table 1 sum-
marizes demographic details, components of metabolic 
syndrome, insulin resistance, and CD-4 counts in the ART-
treated and ART-naïve groups.
Applying NCEP–ATP III criteria, a total of 16 patients out 
of 60 were diagnosed to have metabolic syndrome. Of these, 
13 (81.3%) were on ART, while three (18.7%) were not treated 
with ART (P = 0.028). Of the 60 patients, all had at least one 
component of metabolic syndrome. Four patients fulfilled four 
criteria, and all of them were on ART. The details of the number 
of patients with combinations of criteria are demonstrated in 
Figure 1. The majority of patients with metabolic syndrome 
were males (12/16). When the patients with metabolic syn-
drome were grouped into two, based on age (age #40 years 
and age .40 years), nine were aged 40 years or younger. 
Four patients with metabolic syndrome had body mass index 
(BMI) less than 18.5, 10 had BMI ranging from 18.5 to 24.9, 
and two had BMI more than 25. There was none in the obese 
range with BMI above 30. Among the parameters used for 
diagnosis of metabolic syndrome, the most observed was low 
HDL, occurring in all patients. The details of distribution of 
individual components in patients with metabolic syndrome 
are graphically represented in Figure 2.
For evaluating the occurrence of metabolic syndrome 
with respect to the type of ART, the patients were classified 
into three groups: 1) nonprotease inhibitor (PI), nonstavudine 
(d4T), 2) non-PI d4T, and 3) PI-based regimens. Of the 30 
patients in the ART group, three were exposed to PIs, 18 
to d4T, and nine received the non-PI, non-d4T regime. All 
three patients exposed to PI had metabolic syndrome. In 
the non-PI d4T group, 6 out of 18 had metabolic syndrome, 
and in the non-PI, non-d4T group 4 out of 9 had metabolic 
syndrome.
IR was detected in 24 (40%) patients in the study group 
with a cutoff value of 1.93 for HOMA. Of these, 15 (62.5%) 
were on ART, while nine (37.5%) were ART naïve (P = 0.11). 
Thirteen were aged 40 years or less, whereas the rest were 
Table 1 comparison between ArT-treated and ArT-naïve groups
Study characteristic ART (n = 30) ART-naïve (n = 30) P value
Mean SD Mean SD
Age (years) 41.63 10.94 40.60 9.48 0.697
Duration of disease (months) 53.03 27.76 17.20 9.18 ,0.001
Male/female  23/7 – 21/9 – –
BMI (kg/m2) 20.27 3.82 18.41 4.27 0.080+
Waist circumference (cm) 82.7 11.88 76.7 9.64 0.036
systolic BP (mm hg) 125.67 18.51 114.13 11.60 0.005
Diastolic BP (mm hg) 80.60 9.13 75.60 8.23 0.030
Fasting blood glucose (mg/dL) 95 25.16 89.53 19.6 0.352
Two-hour OGTT blood glucose (mg/dL) 111.33 58.47 131.33 28.55 0.094
hOMA 2.50 2.68 1.80 1.93 0.265
Total cholesterol (mg/dL) 157.47 43.58 149.17 39.92 0.445
hDL cholesterol (mg/dL) 32.87 13.27 25.53 9.42 0.017
LDL cholesterol (mg/dL) 86.92 32.91 78.50 21.63 0.281
Triglycerides (mg/dL) 201.37 163.66 155.43 70.14 0.163
cD-4 counts (cells/μL) 210.23 172.89 170.67 131.40 0.322
Abbreviations: ArT, antiretroviral therapy; BMI, body mass index; BP, blood pressure; hDL, high-density lipoprotein; hOMA, homeostasis assessment; LDL, low-density 
lipoprotein; OGTT, oral glucose tolerance test; sD, standard deviation.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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over this age. Eighteen patients with IR were male, and 
six female. In patients with IR, BMI in seven patients was 
less than 18.5, and in 13 patients, between 18.5 and 24.9. 
Two patients with IR had BMI in the 25.0–29.9 range, and 
two were obese with BMI over 30. IR was present in 12 out 
of 16 patients (75%) with metabolic syndrome. Looking at 
various treatment regimens, all three patients in the PI group 
had IR. In the d4T group, seven out of 18, and in the non-d4T 
group, five out of nine had IR.
In the ART-naïve group, five patients had IFG, two had 
IGT, and two had diabetes. In the ART-treated group, three 
had IFG, two had IGT, two had both IFG and IGT, and six 
had diabetes.
Discussion
The results of the study show that there is an increased 
prevalence of metabolic syndrome and IR in patients 
treated with ART. In our study, the overall prevalence of 
metabolic syndrome in HIV-positive patients was 26.6%; 
43.3% in the ART-treated group, and 10% in the ART-
naïve group. These results showed a statistically significant 
increase in the ART group (P = 0.028). Studies from Spain 
and other parts of the world have reported prevalence rates 
of 17%–18% on larger HIV populations using NCEP–ATP 
III criteria.9,10 Indian studies on uninfected individuals have 
reported prevalence rates ranging from 18.4% to 30.9% 
using NCEP–ATP III criteria.11,12 Thus, in our study the 
overall prevalence rate appears to be similar to the Indian 
general population but higher than other HIV populations. 
The prevalence in our ART-treated group is much higher 
at 43.3%. Insulin resistance based on HOMA values was 
present in 75% of our patients with metabolic syndrome, 
thereby reiterating its pivotal role in its pathogenesis of 
this condition.
It is of interest that all the patients included in the study 
had at least one criterion for metabolic syndrome, and the 
most observed was low HDL. In the Spanish study, of the total 
710 study patients (both ART-treated and -naïve), one or more 
criteria were fulfilled by 69.3%, two or more by 35.8%, three 
or more by 17%, four or more by 4.5%, and all five criteria 
were seen only in one patient.9 Though not directly   comparable, 
these results suggest that unlike in our patients, 31.7% did not 
have any feature of metabolic syndrome, implying that these 
metabolic derangements may be more prevalent in the Indian 
population. In our study, low HDL cholesterol was the most 
observed parameter, whereas in the Spanish study, hyper-
triglyceridemia was the most commonly recognized. Despite 
this difference, the dyslipidemia observed in our patients is 
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concordant with HIV associated dyslipidemia and is a con-
firmed risk factor for macrovascular disease.13
The mechanism of IR and metabolic   syndrome in nucleo-
side reverse transcriptase inhibitor-treated patients is postu-
lated to be mitochondrial toxicity.14 It should be kept in mind 
here that affluent nations have moved on to less toxic drugs, 
while developing countries like India still administer these 
drugs as part of national treatment   programs.15 The individual 
contributions of drugs could not be assessed in our study 
due to inadequate   numbers of patients, though 10 out of 27 
patients on nucleoside reverse transcriptase inhibitor-based 
regimes had metabolic s  yndrome, and 12 out of 27 had IR. 
All the three patients on protease inhibitors in our ART-treated 
group had metabolic syndrome and IR.
Both fasting and post-glucose load blood glucose values 
suggest a high proportion of patients with dysglycemia, with 
six patients in the ART group satisfying diagnostic criteria for 
diabetes. In the context of high usage of nucleoside reverse 
transcriptase inhibitors in our ART regimes, such results 
appear alarming. It is to be noted here that nucleoside reverse 
transcriptase inhibitors used as first-line drugs in India have 
been strongly implicated in the development of insulin 
  resistance and subsequent diabetes.16
The number of patients with metabolic syndrome in the 
ART-naïve group was three out of a total of 30. One notable 
difference between ART-treated and ART-naïve patients 
was the duration of disease. However, this bias cannot be 
fully eliminated as it is unethical to deny therapy to patients 
whose CD4 counts fall to recommended levels to commence 
therapy. It is also of note that, 9 out of 24 patients who had 
IR were not on ART, while 15 were. In   addition, dysglyce-
mia was observed in nine patients in the ART group. While 
mitochondrial toxicity is responsible for IR in nucleoside 
reverse transcriptase inhibitor-treated patients, HIV proteins 
Tat, Vpr, Vif, Rev, and Nef, as well as inflammatory cytokines 
interleukin-2 and tumor necrosis factor-α are implicated in 
ART-naïve patients.1
The BMI of our patients, both with metabolic syndrome 
and insulin resistance, was mostly in the range 18.5–24.9, 
in keeping with the lean fat Indian phenotype with central 
  obesity.4 The ages of patients with IR and metabolic syn-
drome show a tendency towards younger groups, in contrast 
to Western studies where mean age of HIV-infected patients 
with these conditions is higher.9,10 The increased cardiovas-
cular risk for South Asians with central obesity has been 
extensively studied.3,4 Also, the future risk for development 
of diabetes and cardiovascular risk in patients with metabolic 
syndrome is well established.17 An increased cerebro- and 
cardiovascular risk due to metabolic syndrome in HIV has 
been observed by the Data   Collection on Adverse Events 
of Anti-HIV Drugs (DAD) study.2   However, in a risk-prone 
Indian population, the additional burden conferred by ART/
HIV-induced metabolic syndrome needs to be evaluated. If 
proven, this will have implications on future drug policies 
for HIV-infected patients.
Despite the limitation of the small number of patients in 
our study, there is an increase in metabolic syndrome, dia-
betes mellitus, and insulin resistance in patients on ART in 
southern India. Larger population-based studies are needed 
to assess the actual prevalence of metabolic syndrome and IR 
and the macrovascular risk conferred by these conditions.
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